Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lymphoma, Large B-Cell, Diffuse | 5 | 2021 | 15 | 2.050 |
Why?
|
| Adenine | 2 | 2021 | 15 | 1.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2023 | 401 | 1.540 |
Why?
|
| Piperidines | 2 | 2021 | 125 | 1.470 |
Why?
|
| Lymphoma, Non-Hodgkin | 2 | 2020 | 20 | 1.450 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 546 | 1.000 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2020 | 77 | 0.900 |
Why?
|
| Leg | 1 | 2021 | 56 | 0.810 |
Why?
|
| Testosterone | 1 | 2021 | 48 | 0.780 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2020 | 17 | 0.770 |
Why?
|
| Cyclophosphamide | 2 | 2020 | 25 | 0.770 |
Why?
|
| Deglutition Disorders | 1 | 2020 | 50 | 0.740 |
Why?
|
| Receptors, CCR4 | 1 | 2019 | 3 | 0.730 |
Why?
|
| Lymphoma, T-Cell | 1 | 2019 | 5 | 0.720 |
Why?
|
| Azepines | 1 | 2019 | 2 | 0.720 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 28 | 0.710 |
Why?
|
| Nanoparticles | 1 | 2020 | 48 | 0.700 |
Why?
|
| Pyrimidines | 1 | 2019 | 60 | 0.680 |
Why?
|
| Stroke Volume | 1 | 2021 | 280 | 0.660 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2023 | 4 | 0.650 |
Why?
|
| Quality of Life | 1 | 2021 | 820 | 0.540 |
Why?
|
| Heart Failure | 1 | 2021 | 573 | 0.530 |
Why?
|
| Humans | 14 | 2023 | 29220 | 0.370 |
Why?
|
| Cell Line, Tumor | 2 | 2020 | 681 | 0.310 |
Why?
|
| Recurrence | 2 | 2021 | 235 | 0.220 |
Why?
|
| Treatment Outcome | 5 | 2021 | 3108 | 0.220 |
Why?
|
| Aged | 5 | 2021 | 9515 | 0.210 |
Why?
|
| Middle Aged | 5 | 2021 | 10872 | 0.200 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 83 | 0.190 |
Why?
|
| Radioimmunotherapy | 1 | 2020 | 1 | 0.190 |
Why?
|
| Killer Cells, Natural | 1 | 2020 | 24 | 0.190 |
Why?
|
| Antigens, CD20 | 1 | 2020 | 7 | 0.190 |
Why?
|
| HLA-DR Antigens | 1 | 2020 | 8 | 0.190 |
Why?
|
| Immunophenotyping | 1 | 2020 | 49 | 0.190 |
Why?
|
| Tissue Distribution | 1 | 2020 | 55 | 0.180 |
Why?
|
| Quinolines | 1 | 2020 | 27 | 0.180 |
Why?
|
| Drug Compounding | 1 | 2020 | 36 | 0.180 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2019 | 1 | 0.180 |
Why?
|
| Lymphoma, T-Cell, Cutaneous | 1 | 2019 | 6 | 0.180 |
Why?
|
| Drug Eruptions | 1 | 2019 | 8 | 0.180 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2020 | 113 | 0.180 |
Why?
|
| Radiopharmaceuticals | 1 | 2020 | 88 | 0.180 |
Why?
|
| Imidazoles | 1 | 2020 | 104 | 0.180 |
Why?
|
| Drug Synergism | 1 | 2019 | 67 | 0.180 |
Why?
|
| Cell Cycle | 1 | 2019 | 69 | 0.170 |
Why?
|
| Thrombocytopenia | 1 | 2019 | 32 | 0.170 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 90 | 0.170 |
Why?
|
| Cytarabine | 1 | 2019 | 52 | 0.170 |
Why?
|
| Mice, Transgenic | 1 | 2019 | 249 | 0.170 |
Why?
|
| Outpatients | 1 | 2019 | 49 | 0.170 |
Why?
|
| Mice, Nude | 1 | 2019 | 276 | 0.170 |
Why?
|
| Drug Therapy, Combination | 1 | 2019 | 273 | 0.170 |
Why?
|
| Liver Diseases | 1 | 2019 | 61 | 0.170 |
Why?
|
| Cisplatin | 1 | 2019 | 69 | 0.170 |
Why?
|
| Dexamethasone | 1 | 2019 | 42 | 0.170 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 196 | 0.170 |
Why?
|
| Salvage Therapy | 1 | 2019 | 118 | 0.160 |
Why?
|
| Aged, 80 and over | 3 | 2020 | 3728 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2019 | 249 | 0.160 |
Why?
|
| Animals | 2 | 2020 | 7302 | 0.160 |
Why?
|
| Adult | 5 | 2023 | 8468 | 0.160 |
Why?
|
| Apoptosis | 1 | 2019 | 337 | 0.150 |
Why?
|
| Male | 5 | 2021 | 17876 | 0.150 |
Why?
|
| Skin Neoplasms | 1 | 2019 | 206 | 0.150 |
Why?
|
| Mutation | 1 | 2019 | 466 | 0.150 |
Why?
|
| Kidney Diseases | 1 | 2019 | 239 | 0.140 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 981 | 0.140 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2019 | 337 | 0.140 |
Why?
|
| Neoplasms | 1 | 2020 | 612 | 0.120 |
Why?
|
| Mice | 1 | 2019 | 2372 | 0.120 |
Why?
|
| Female | 4 | 2021 | 18241 | 0.100 |
Why?
|
| Prognosis | 2 | 2023 | 1363 | 0.080 |
Why?
|
| Prospective Studies | 2 | 2021 | 2027 | 0.070 |
Why?
|
| Retrospective Studies | 2 | 2021 | 3122 | 0.060 |
Why?
|
| Young Adult | 2 | 2020 | 2413 | 0.060 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2021 | 10 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 525 | 0.050 |
Why?
|
| Vincristine | 1 | 2020 | 15 | 0.050 |
Why?
|
| Prednisone | 1 | 2020 | 43 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2021 | 440 | 0.050 |
Why?
|
| Doxorubicin | 1 | 2020 | 55 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2020 | 81 | 0.050 |
Why?
|
| Immunotherapy | 1 | 2020 | 69 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2021 | 231 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2020 | 437 | 0.040 |
Why?
|
| Patient Selection | 1 | 2020 | 257 | 0.040 |
Why?
|
| Disease Progression | 1 | 2020 | 572 | 0.040 |
Why?
|
| Age Factors | 1 | 2021 | 1110 | 0.040 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 788 | 0.040 |
Why?
|
| Risk Assessment | 1 | 2023 | 1313 | 0.040 |
Why?
|
| Time Factors | 1 | 2020 | 2003 | 0.030 |
Why?
|
| Adolescent | 1 | 2020 | 3265 | 0.030 |
Why?
|
| United States | 1 | 2020 | 3648 | 0.030 |
Why?
|